<DOC>
	<DOCNO>NCT01356849</DOCNO>
	<brief_summary>Prospective , Randomized , Double-Blind , Placebo-Controlled Multicenter Study . The objective study evaluate efficacy safety daily administration atrasentan tablet ( low dose high dose ) compare placebo reduce residual albuminuria Type 2 diabetic patient nephropathy treat maximum tolerated label dose Renin Angiotensin System ( RAS ) inhibitor . If patient already receive maximum tolerate labeled daily dose RAS inhibitor diuretic , he/she complete 4 week Run-in Period dose adjust . If patient currently receive maximum label daily dose RAS inhibitor dose titrate maximum tolerated label dose course 4 8 week Run-in Period . It expect subject receive diuretic diuretic add titrated period maximize RAS inhibition . Following titration maximum tolerate labeled dose , patient complete additional 4 week Run-In Period unchanged dos RAS inhibitor diuretic , unless medically contraindicate . The randomization stratify base country subject enrol study , Week -1 Urinary Albumin Creatinine Ratio ( UACR ) level ( &lt; = 1000 mg/g [ 113 mg/mmol ] , &gt; 1000 mg/g [ 113 mg/mmol ] ) . Within stratum , subject randomly assign 1:2:2 ratio one follow blind treatment group : Group A - Placebo daily ( QD ) Group B - low dose atrasentan QD Group C - high dose atrasentan QD After 12 week study drug treatment , subject follow 30 day .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Once Daily Administration Atrasentan Tablets ( Low High ) Compared Placebo Reducing Residual Albuminuria Type 2 Diabetic Patients With Nephropathy Who Are Treated With Maximum Tolerated Labeled Dose Renin Angiotensin System ( RAS ) Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>Patient &gt; = 18 year old . Patient Type 2 diabetes treat least one anti hyperglycemic medication within 12 month prior Screening Period . Patient currently receive angiotensin convert enzyme inhibitor ( ACEi ) Angiotensin II receptor blocker ( ARB ) ( Renin Angiotensin System ( RAS ) inhibitor ) . For entry Runin Period patient must satisfy follow criterion base Screening laboratory value : Estimated glomerular filtration rate ( eGFR ) ≥ 30 ≤ 75 mL/min/1.73m2 Epidemiology Collaboration ( EPI ) formula Urinary Albumin Creatinine Ratio ( UACR ) &gt; = 300 &lt; = 3500 mg/g determine geometric mean two morning void urine specimen obtain Screening visit ( UACR &gt; = 34 mg/mmol &lt; = 396 mg/mmol ) Serum albumin &gt; = 3.0 g/dL ( 30 g/L ) Btype Natriuretic Peptide ( BNP ) &lt; = 200 pg/mL ( 57.8 pmol/L ) * Negative serum pregnancy test female patient Systolic Blood Pressure ( SBP ) &gt; = 110 mmHg &lt; = 180 mmHg Glucosylated hemoglobin A1c ( HbA1c ) &lt; = 12 % For entry Treatment Period patient must satisfy follow criterion base last visit Runin Period laboratory value : Renin Angiotensin System ( RAS ) inhibitor maximum tolerate label dose previous 4 week adjustment dose Diuretic dose unless medically contraindicate ( exception loop diuretic &gt; = 120 mg QD furosemide &gt; = 3.0 mg QD bumetanide &gt; = 150 mg QD ethacrynic acid &gt; = 60 mg QD torasemide ) Urinary Albumin Creatinine Ratio ( UACR ) &gt; = 200 &lt; = 3500 mg/g determine median three morning void urine specimen obtain prior Week 1 visit ( UACR &gt; = 23 mg/mmol &lt; = 396 mg/mmol ) Systolic blood pressure ( SBP ) &gt; = 110 mmHg &lt; = 160 mmHg Serum Potassium &lt; = 5.5 mEq/L ( 5.5 mmol/L ) Negative serum pregnancy test female patient Patient history moderate severe edema , facial edema unrelated trauma , history myxedema prior 6 month Screening . Patient receive loop diuretic &gt; = 120 mg QD furosemide &gt; = 3.0 mg QD bumetanide &gt; = 150 mg QD ethacrynic acid &gt; = 60 mg QD torasemide . Patient history pulmonary edema . Patient history pulmonary hypertension , lung disease require oxygen therapy ( i.e. , chronic obstructive pulmonary disease , emphysema , pulmonary fibrosis ) . Patient history orthostatic hypotension within past 6 month define presence supinetostanding blood pressure decrease &gt; = 20 mmHg systolic &gt; = 10 mmHg diastolic within 3 minute stand .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Endothelin Receptor Antagonists</keyword>
	<keyword>Proteinuria</keyword>
</DOC>